FOLD

$14.37

Post-MarketAs of Mar 17, 8:00 PM UTC

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$14.37
Potential Upside
5%
Whystock Fair Value$15.09
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Gala...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.51B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.49
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-11.58%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.72

Recent News

Simply Wall St.
Mar 15, 2026

Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside

Why Amicus Therapeutics stands out today Amicus Therapeutics (FOLD) has drawn attention recently as investors weigh its current share price of US$14.37 against the company’s rare disease portfolio, revenue of US$634.21 million, and net loss of US$27.11 million. See our latest analysis for Amicus Therapeutics. At a share price of US$14.37, Amicus Therapeutics has seen a 32.08% 3 month share price return, while its 1 year total shareholder return of 61.46% contrasts with more modest multi year...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Investor's Business Daily
Mar 10, 2026

Viking Therapeutics Stock Gets RS Rating Upgrade

Viking Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 9, 2026

Rice Hall James Loads Up on BIRK With 466,000 Shares Bought

Birkenstock sells premium footwear via global channels, reaching comfort-focused consumers across major international markets.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 9, 2026

Rice Hall James Buys QuidelOrtho Stock

QuidelOrtho develops diagnostic technologies for healthcare providers worldwide, spanning labs, clinics, and retail settings.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Motley Fool
Mar 9, 2026

Rice Hall James Buys Stride Stock

Stride delivers online and blended education solutions for K-12, career, and adult learners through proprietary technology platforms.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.